Targeted treatment approaches for mantle cell lymphoma

Czech version

Authors: A. Hrušková ¹; P. Klener ²; A. Obr ¹
Authors‘ workplace: Hemato-onkologická klinika LF UP a FN Olomouc ¹; I. interní klinika – klinika hematologie 1. LF UK a VFN v Praze ²
Published in: Transfuze Hematol. dnes,32, 2026, No. 3, p. 168-180.
Category: Review/Educational Papers
doi: https://doi.org/10.48095/cctahd202619

Overview

Mantle cell lymphoma (MCL) is a relatively rare subtype of non-Hodgkin lymphoma. For many years, it was considered an incurable disease for the majority of patients. Despite the establishment of validated prognostic indices and an improved understanding of the disease biology, treatment selection has until recently remained largely independent of prognostic and predictive disease factors. An innovative approach now involves the use of Bruton’s tyrosine kinase inhibitors (BTKi) in the first-line setting, either in combination with chemotherapy or with other targeted agents. In relapsed patients after failure of covalent BTKi therapy, novel options have emerged, including chimeric antigen receptor (CAR) T-cell therapy and non-covalent BTKi. With these advances in both prognostic assessment and therapeutic strategies, long-term remission can now be achieved in a substantial proportion of patients. This review summarizes the current therapeutic landscape of MCL with an emphasis on modern targeted approaches.

Keywords:

mantle cell lymphoma – CAR-T therapy – BTK inhibitors

Sources

1. Belada D, Trněný M. Diagnostické a léčebné postupy u nemocných s maligními lymfomy. XV. vydání. Kooperativní lymfomová skupina; 2025. [online]. Dostupné z: https: //www.lymphoma.cz

2. Monga N, Virchow R, Lin T, et al. Systematic literature review of the global burden of illness of mantle cell lymphoma. Curr Med Res Opin. 2020; 36 (5): 843–852. doi: 10.1080/03007995.2020.1742101.

3. Smedby KE, Hjalgrim H. Epidemiology and etiology of mantle cell lymphoma and other non-Hodgkin lymphoma subtypes. Semin Cancer Biol. 2011; 21 (5): 293–298. doi: 10.1016/j.semcancer.2011.09.010.

4. Banks PM, Chan J, Cleary ML, et al. Mantle cell lymphoma. A proposal for unification of morphologic, immunologic, and molecular data. Am J Surg Pathol. 1992; 16 (7): 637–640. doi: 10.1097/00000478-199207000-00001.

5. Harris NL, Jaffe ES, Stein H, et al. A Revised European-American Classification of Lymphoid Neoplasms: A Proposal From the International Lymphoma Study Group. Blood. 1994; 84 (5): 1361–1392. doi: 10.1182/blood.V84.5.1361.1361.

6. Alaggio R, Amador C, Anagnostopoulos I, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms. Leukemia. 2022; 36 (7): 1720–1748. doi: 10.1038/s41375-022-01620-2.

7. Silkenstedt E, Linton K, Dreyling M. Mantle cell lymphoma –⁠ advances in molecular biology, prognostication and treatment approaches. Br J Haematol. 2021; 195 (2): 162–173. doi: 10.1111/bjh.17419.

8. Jain AG, Chang CC, Ahmad S, et al. Leukemic non-nodal mantle cell lymphoma: diagnosis and treatment. Curr Treat Options Oncol. 2019; 20 (12): 85. doi: 10.1007/s11864-019-0684-8.

9. Khanlari M, Lin P, Medeiros LJ, et al. Blastoid and pleomorphic mantle cell lymphoma demonstrate distinct clinicopathologic and genetic features. Am J Surg Pathol. 2023; 47 (8): 849–857. doi: 10.1097/PAS.0000000000002068.

10. Herrmann A, Hoster E, Zwingers T, et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol. 2009; 27 (4): 511–518. doi: 10.1200/JCO.2008. 16.8435.

11. Schulz H, Bohlius J, Trelle S, et al. Chemotherapy plus rituximab versus chemotherapy alone for B-cell non-Hodgkin’s lymphoma. Cochrane Database Syst Rev. 2007; (4): CD003805. doi: 10.1002/14651858.CD003805.pub2.

12. Lenz G, Dreyling M, Hoster E, et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma. J Clin Oncol. 2005; 23 (9): 1984–1992. doi: 10.1200/JCO.2005.08.133.

13. Hermine O, Cheminant M, Morschhauser F, et al. High-dose cytarabine and autologous stem-cell transplantation in mantle cell lymphoma: long-term follow-up of the randomized Mantle Cell Lymphoma Younger Trial of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2023; 41 (3): 479–484. doi: 10.1200/JCO.22.01780.

14. Jerkeman M, Hoster E, Dreyling M, et al. EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma. HemaSphere. 2025; 9 (10): e70233. doi: 10.1002/hem3.70233.

15. Hoster E, Rosenwald A, Berger F, et al. Prognostic value of Ki-67 index, cytology, and growth pattern in mantle-cell lymphoma: results from randomized trials of the European Mantle Cell Lymphoma Network. J Clin Oncol. 2016; 34 (12): 1386–1394. doi: 10.1200/JCO.2015. 63.8387.

16. Hoster E, Dreyling M, Klapper W, et al. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma. Blood. 2008; 111 (2): 558–565. doi: 10.1182/blood-2007-06-095331.

17. Hoster E, Klapper W, Hermine O, et al. Confirmation of the Mantle-Cell Lymphoma International Prognostic Index in randomized trials of the European Mantle-Cell Lymphoma Network. J Clin Oncol. 2014; 32 (13): 1338–1346. doi: 10.1200/JCO.2013.52.2466.

18. Malarikova D, Jiraskova I, Pytlik R, et al. Concurrent TP53 and CDKN2A gene aberrations in newly diagnosed mantle cell lymphoma correlate with chemoresistance and call for innovative upfront therapy. Cancers (Basel). 2020; 12 (8): 2120. doi: 10.3390/cancers12082120.

19. Halldórsdóttir AM, Lundin A, Murray F, et al. Impact of TP53 mutation and 17p deletion in mantle cell lymphoma. Leukemia. 2011; 25 (12): 1904–1908. doi: 10.1038/leu. 2011.162.

20. Sarkozy C, Terré C, Jardin F, et al. Complex karyotype in mantle cell lymphoma is a strong prognostic factor for the time to treatment and overall survival, independent of the MCL international prognostic index. Genes Chromosomes Cancer. 2014; 53 (2): 106–114. doi: 10.1002/gcc.22123.

21. Hill HA, Lee H, Wu C, et al. Genetic mutations and features of mantle cell lymphoma: a systematic review and meta-analysis. Blood Adv. 2020; 4 (13): 2927–2938. doi: 10.1182/bloodadvances. 2019001350.

22. Eskelund CW, Dahl C, Hansen JW, et al. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy. Blood. 2017; 130 (17): 1903–1910. doi: 10.1182/blood-2017-04-779736.

23. Greenwell IB, Staton AD, McDonnell K, et al. Complex karyotype in patients with mantle cell lymphoma predicts inferior survival and poor response to intensive induction therapy. Cancer. 2018; 124 (11): 2306–2315. doi: 10.1002/cncr.31328.

24. Obr A, Kralova R, Mocikova H, et al. TP53 mutation and complex karyotype portends a dismal prognosis in patients with mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2018; 18 (11): 762–768. doi: 10.1016/j.clml.2018.07.282.

25. Eyre TA, Hiddemann W, McKay P, et al. Lymphomas: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. Ann Oncol. 2025; 36 (11): 1263–1284. doi: 10.1016/j.annonc.2025.07.014.

26. Scheubeck G, Neumann M, Hoster E, et al. Clinical outcome of mantle cell lymphoma patients with high-risk disease (high-risk MIPI-c or high p53 expression). Leukemia. 2023; 37 (9): 1887–1894. doi: 10.1038/s41375-023-01977-y.

27. Stefancikova L, Moulis M, Fabian P, et al. Loss of the p53 tumor suppressor activity is associated with negative prognosis of mantle cell lymphoma. Int J Oncol. 2010; 36 (3): 699–706. doi: 10.3892/ijo_00000545.

28. Kumar A. Who is a candidate for watch and wait therapy in mantle cell lymphoma? Clin Lymphoma Myeloma Leuk. 2019; 19 (Suppl): S109–S111. doi: 10.1016/j.clml.2019.07.437.

29. Dabaja BS, Tsang RW, Hoppe RT, et al. Early-stage mantle cell lymphoma: a retrospective analysis from the International Lymphoma Radiation Oncology Group (ILROG). Ann Oncol. 2017; 28 (9): 2185–2190. doi: 10.1093/annonc/mdx334.

30. Eskelund CW, Kolstad M, Jerkeman H, et al. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): prolonged remissions without survival plateau. Br J Haematol. 2016; 175 (3): 410–418. doi: 10.1111/bjh.14241.

31. Chihara D, Cheah MA, Westin JR, et al. Rituximab plus hyper-CVAD alternating with MTX/Ara-C in patients with newly diagnosed mantle cell lymphoma: 15-year follow-up of a phase II study from the MD Anderson Cancer Center. Br J Haematol. 2016; 172 (1): 80–88. doi: 10.1111/bjh.13796.

32. Klener P, Klánová M, Trněný M, et al. Rituximab maintenance significantly prolongs progression-free survival of patients with newly diagnosed mantle cell lymphoma treated with the Nordic MCL2 protocol and autologous stem cell transplantation. Am J Hematol. 2019; 94 (2): E50–E53. doi: 10.1002/ajh.25362.

33. Sarkozy C, Salles G, Casasnovas O, et al. Long-term follow-up of rituximab maintenance in young patients with mantle-cell lymphoma included in the LYMA trial: a LYSA study. J Clin Oncol. 2024; 42 (7): 769–773. doi: 10.1200/JCO.23.01586.

34. Le Gouill S, Thieblemont C, Moreau P, et al. Rituximab after autologous stem-cell transplantation in mantle-cell lymphoma. N Engl J Med. 2017; 377 (13): 1250–1260. doi: 10.1056/NEJMoa1701769.

35. Dreyling M, Doorduijn J, Giné E, et al. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network. Lancet. 2024; 403 (10441): 2293–2306. doi: 10.1016/S0140-6736 (24) 00184-3.

36. Dreyling M, Doorduijn J, Giné E, et al. Role of Autologous Stem Cell Transplantation in the Context of Ibrutinib-Containing First-Line Treatment in Younger Patients with Mantle Cell Lymphoma: Results from the Randomized Triangle Trial by the European MCL Network. Blood. 2024; 144 (Suppl 1): 240. doi: 10.1182/blood-2024-200735.

37. Ladetto M, Gutmair K, Doorduijn JK, et al. Impact of Rituximab Maintenance Added to Ibrutinib-Containing Regimens with and without ASCT in Younger, Previously Untreated MCL Patients: An Analysis of the Triangle Data Embedded in the Multiply Project. Blood. 2024; 144 (Suppl 1): 237. doi: 10.1182/blood-2024-201441.

38. Wang ML, Jurczak W, Jerkeman M, et al. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma. N Engl J Med. 2022; 386 (26): 2482–2494. doi: 10.1056/NEJMoa 2201817.

39. Wang M, Salek D, Belada D, et al. Acalabrutinib Plus Bendamustine-Rituximab in Untreated Mantle Cell Lymphoma. J Clin Oncol. 2025; 43 (20): 2276–2284. doi: 10.1200/JCO-25-00690.

40. Klener P, Mayer J, Pytlik R, et al. Alternating R-CHOP and R-cytarabine is a safe and effective regimen for transplant-ineligible patients with a newly diagnosed mantle cell lymphoma. Hematol Oncol. 2018; 36 (1): 110–115. doi: 10.1002/hon.2483.

41. Visco C, Michelutti A, Rigacci L, et al. Rituximab, bendamustine, and low-dose cytarabine as induction therapy in elderly patients with mantle cell lymphoma: a multicentre, phase 2 trial from Fondazione Italiana Linfomi. Lancet Haematol. 2017; 4 (1): e15–e23. doi: 10.1016/S2352-3026 (16) 30185-5.

42. Flinn IW, van der Jagt R, Kahl BS, et al. First-Line Treatment of Patients With Indolent Non-Hodgkin Lymphoma or Mantle-Cell Lymphoma With Bendamustine Plus Rituximab Versus R-CHOP or R-CVP: Results of the BRIGHT 5-Year Follow-Up Study. J Clin Oncol. 2019; 37 (12): 984–991. doi: 10.1200/JCO.18.00605.

43. Robak T, Huang H, Jin J, et al. Frontline bortezomib, rituximab, cyclophosphamide, doxorubicin, and prednisone (VR-CAP) versus rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in transplantation-ineligible patients with newly diagnosed mantle cell lymphoma: final overall survival results of a randomised, open-label, phase 3 study. Lancet Oncol. 2018; 19 (11): 1449–1458. doi: 10.1016/S1470-2045 (18) 30685-5.

44. Rummel MJ, Samaridis J, Kofler C, et al. Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial. Lancet. 2013; 381 (9873): 1203–1210. doi: 10.1016/S0140-6736 (12) 61763-2.

45. Lewis DJ, Wierda WG, Bowen D, et al. Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH): a randomised, open-label, phase 2/3 superiority trial. Lancet. 2025; 406 (10514): 1953–1968. doi: 10.1016/S0140-6736 (25) 01432-1.

46. Jerkeman M, Brown JR, Rule S, et al. Acalabrutinib and rituximab in elderly patients with newly diagnosed mantle cell lymphoma including a matched population-based external comparator—the Nordic Lymphoma Group NLG-MCL8 (ALTAMIRA) phase II trial. Blood. 2024; 144 (Suppl 1): 747–748. doi: 10.1182/blood-2024-192939

47. Tilch M-K, Rule S, Zinzani PL, et al. Trials in Progress: Carman—an international, randomized phase II study evaluating early treatment intensification in patients with high risk mantle cell lymphoma using CAR-T-cell treatment after an abbreviated induction therapy with rituximab and ibrutinib and 6 months ibrutinib maintenance (Arm A) as compared to standard of care induction and maintenance (Arm B). Blood. 2024; 144 (Suppl 1): 4422.3. doi: 10.1182/blood-2024-206931.

48. Kumar A, Maddocks KJ, Herrera AF, et al. Zanubrutinib, obinutuzumab, and venetoclax for first-line treatment of mantle cell lymphoma with a TP53 mutation. Blood. 2025; 145 (5): 497–507. doi: 10.1182/blood.2024025563.

49. Wang M, Portell CA, Seymour JF, et al. Acalabrutinib plus venetoclax and rituximab in treatment-naive mantle cell lymphoma: 2-year safety and efficacy analysis. Blood Adv. 2024; 8 (17): 4539–4548. doi: 10.1182/bloodadvances.2023012424.

50. Le Gouill S, Morschhauser F, Chiron D, et al. Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. Blood. 2021; 137 (7): 877–887. doi: 10.1182/blood.2020 008727.

51. Le Gouill S, Morschhauser F, Chiron D, et al. Ibrutinib, Venetoclax Plus CD20 Monoclonal Ab Provides Very High MRD Negativity in Previously Untreated MCL Patients, Initial Results of OASIS II, a Randomized Phase 2 Trial. Blood. 2024; 144 (Suppl 1): 745. doi: 10.1182/blood-2024-194357.

52. Ben Barouch S, Kuruvilla J, Tsang RW, et al. Radiotherapy in mantle cell lymphoma: A literature review. Hematol Oncol. 2020; 38 (3): 223–228. doi: 10.1002/hon.2708.

53. Wang ML, Rule S, Martin P, et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2013; 369 (6): 507–516. doi: 10.1056/NEJMoa1306220.

54. Rule S, Dreyling M, Goy A, et al. Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. Br J Haematol. 2017; 179 (3): 430–438. doi: 10.1111/bjh.14870.

55. Obr A, Mocikova H, Benesova K, et al. Ibrutinib in mantle cell lymphoma: a real-world retrospective multicenter analysis of 77 patients treated in the Czech Republic. Ann Hematol. 2023; 102 (1): 107–115. doi: 10.1007/s00277-022-05023-2.

56. Le Gouill S, Długosz-Danecka M, Rule S, et al. Final results and overall survival data from a phase II study of acalabrutinib monotherapy in patients with relapsed/refractory mantle cell lymphoma, including those with poor prognostic factors. Haematologica. 2024; 109 (1): 343–350. doi: 10.3324/haematol.2022.282469.

57. Song Y, Zhou K, Zou D, et al. Zanubrutinib in relapsed/refractory mantle cell lymphoma: long-term efficacy and safety results from a phase 2 study. Blood. 2022; 139 (21): 3148–3158. doi: 10.1182/blood.2021014162.

58. Handunnetti SM, Tam CS, Yao S, et al. Seven-year outcomes of venetoclax-ibrutinib therapy in mantle cell lymphoma: durable responses and treatment-free remissions. Blood. 2024; 144 (8): 867–872. doi: 10.1182/blood. 2023023388.

59. Wang M, Rule S, Goy A, et al. Ibrutinib plus venetoclax in relapsed or refractory mantle cell lymphoma (SYMPATICO): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2025; 26 (2): 200–213. doi: 10.1016/S1470-2045 (24) 00682-X.

60. Melani C, Armand P, Younes A, et al. Phase 1b/2 study of venetoclax, ibrutinib, prednisone, obinutuzumab, and lenalidomide (ViPOR) in relapsed/refractory and treatment-naïve mantle cell lymphoma: preliminary analysis of safety, efficacy, and minimal residual disease. Blood. 2024; 144 (Suppl 1): 750. doi: 10.1182/blood-2024-197956.

61. Forsgren E, Jerkeman M, Eskelund CW, et al. Ibrutinib, lenalidomide, and rituximab in relapsed mantle cell lymphoma: long-term follow-up of the Nordic Lymphoma Group MCL6 Philemon trial. HemaSphere. 2025; 9 (3): e70101. doi: 10.1002/hem3.70101.

62. Mato AR, Shah NN, Jurczak W, et al. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study. Lancet. 2021; 397 (10277): 892–901. doi: 10.1016/S0140-6736 (21) 00224-5.

63. Shah NN, Maddocks K, Woyach JA, et al. Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial. Haematologica. 2025; 110 (1): e1. doi: 10.3324/haematol.2024.285754.

64. Cohen JB, Mato AR, Goy A, et al. Pirtobrutinib in relapsed/refractory mantle cell lymphoma patients with prior cBTKi: safety and efficacy including high-risk subgroup analyses from the phase 1/2 BRUIN study. Blood. 2023; 142 (Suppl 1): 981. doi: 10.1182/blood-2023-181627.

65. Woyach JA, Stephens DM, Allan JN, et al. First-in-human study of the reversible BTK inhibitor nemtabrutinib in patients with relapsed/refractory chronic lymphocytic leukemia and B-cell non-Hodgkin lymphoma. Cancer Discov. 2024; 14 (1): 66–75. doi: 10.1158/2159-8290.CD-23-0670.

66. Deng LJ, Fan L, Wang L, et al. Orelabrutinib for the treatment of relapsed or refractory mantle cell lymphoma: a phase 1/2, open-label, multicenter, single-arm study. Blood Adv. 2023; 7 (16): 4349–4357. doi: 10.1182/blood advances.2022009168.

67. Wang M, Munoz J, Goy A, et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N Engl J Med. 2020; 382 (14): 1331–1342. doi: 10.1056/NEJMoa1914347.

68. Wang M, Munoz J, Goy A, et al. Three-year follow-up of KTE-X19 in patients with relapsed/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study. J Clin Oncol. 2023; 41 (3): 555–567. doi: 10.1200/JCO.21.02370.

69. National Cancer Institute. Common Terminology Criteria for Adverse Events (CTCAE) v5.0. Bethesda (MD): National Institutes of Health; 2017.

70. Wang Y, Jain P, Nastoupil LJ, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium. J Clin Oncol. 2023; 41 (14): 2594–2606. doi: 10.1200/JCO.22.01797.

71. O’Reilly MA, Eyre TA, Phillips EH, et al. Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in the United Kingdom: a real-world intention-to-treat analysis. HemaSphere. 2024; 8 (6): e87. doi: 10.1002/hem3.87.

72. Herbaux C, Gauthier J, Manson G, et al. Brexucabtagene autoleucel in relapsed or refractory mantle cell lymphoma, intention-to-treat use in the DESCAR-T registry. Haematologica. 2024; 109 (11): 3745–3750. doi: 10.3324/haematol.2023.284786.

73. Ahmed N, Perales MA, Shah NN, et al. Real-world outcomes of brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma: a CIBMTR analysis. Blood Adv. 2025 Jul. doi: 10.1182/bloodadvances.2024015014.

74. Wang M, Munoz J, Goy A, et al. Lisocabtagene maraleucel in relapsed/refractory mantle cell lymphoma: primary analysis of the mantle cell lymphoma cohort from TRANSCEND NHL 001, a phase I multicenter seamless design study. J Clin Oncol. 2024; 42 (10): 1146–1157. doi: 10.1200/JCO.23.02214.

75. Liebers N, Dreger P, Dietrich S, et al. Brexucabtagene autoleucel versus allogeneic hematopoietic cell transplantation in relapsed and refractory mantle cell lymphoma. Blood Cancer Discov. 2025; 6 (3): 182–190. doi: 10.1158/2643-3230.BCD-24-0178.

76. Visco C, Chiappella A, Nassi L, et al. Combination of rituximab, bendamustine, and cytarabine for patients with mantle-cell non-Hodgkin lymphoma ineligible for intensive regimens or autologous transplantation. J Clin Oncol. 2013; 31 (11): 1442–1449. doi: 10.1200/JCO.2012.45.9842.

77. McCulloch R, Visco C, Eyre TA, et al. Efficacy of R-BAC in relapsed, refractory mantle cell lymphoma post BTK inhibitor therapy. Br J Haematol. 2020; 189 (4): 684–688. doi: 10.1111/bjh.16416.

78. Wang M, Fayad L, Wagner-Bartak N, et al. Lenalidomide in combination with rituximab for patients with relapsed or refractory mantle-cell lymphoma: a phase 1/2 clinical trial. Lancet Oncol. 2012; 13 (7): 716–723. doi: 10.1016/S1470-2045 (12) 70200-0.

79. Trněný M, Lamy T, Walewski J, et al. Lenalidomide versus investigator’s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. Lancet Oncol. 2016; 17 (3): 319–331. doi: 10.1016/S1470-2045 (15) 00559-8.

80. Lamm W, Kaufmann H, Raderer M, et al. Bortezomib combined with rituximab and dexamethasone is an active regimen for patients with relapsed and chemotherapy-refractory mantle cell lymphoma. Haematologica. 2011; 96 (7): 1008–1014. doi: 10.3324/haematol. 2011.041392.

81. Phillips TJ, Dickinson M, Morschhauser F, et al. Glofitamab in relapsed/refractory mantle cell lymphoma: results from a phase I/II study. J Clin Oncol. 2025; 43 (3): 318–328. doi: 10.1200/JCO.23.02470.

82. Wang ML, Dickinson M, Goy A, et al. MCL-1493: fixed-duration outpatient subcutaneous mosunetuzumab + polatuzumab vedotin shows robust efficacy in a phase 2 study of relapsed/refractory post-BTK inhibitor mantle cell lymphoma. Clin Lymphoma Myeloma Leuk. 2025; 25 (Suppl): S858. doi: 10.1016/S2152-2650 (25) 02485-1.

83. Cheah CY, George A, Giné E, et al. Central nervous system involvement in mantle cell lymphoma: clinical features, prognostic factors and outcomes from the European Mantle Cell Lymphoma Network. Ann Oncol. 2013; 24 (8): 2119–2123. doi: 10.1093/annonc/mdt139.

84. Trab T, El-Galaly TC, d’Amore F, et al. Secondary central nervous system lymphoma in mantle cell lymphoma: characteristics and risk factors in a Danish nationwide population-based study. Br J Haematol. 2025 Aug. doi: 10.1111/bjh.70082.

85. Conconi A, Franceschetti S, Lobetti-Bodoni C, et al. Risk factors of central nervous system relapse in mantle cell lymphoma. Leuk Lymphoma. 2013; 54 (9): 1908–1914. doi: 10.3109/10428194.2013.767454.

86. McLaughlin N, Eyre TA, Phillips EH, et al. Central nervous system involvement by mantle cell lymphoma. Leuk Lymphoma. 2023; 64 (2): 371–377. doi: 10.1080/10428194.2022.2148211.

87. Rusconi C, Ferreri AJM, Zucca E, et al. Ibrutinib improves survival compared with chemotherapy in mantle cell lymphoma with central nervous system relapse. Blood. 2022; 140 (17): 1907–1916. doi: 10.1182/blood.2022015560.

88. Ahmed G, Perales MA, Shah NN, et al. CAR T-cell therapy in mantle cell lymphoma with secondary CNS involvement: a multicenter experience. Blood Adv. 2024; 8 (13): 3528–3531. doi: 10.1182/bloodadvances.2023012255.

Labels

Haematology Internal medicine Clinical oncology

Guidelines for inherited thrombophilia testing in children

Asciminib – a novel drug for chronic myeloid leukemia with a distinct mechanism of action

Multiple myeloma – from pathogenesis to modern therapy

Emerging therapies for relapsed/refractory follicular lymphoma

Contemporary diagnostic determination of D-dimer plasma concentration

Evaluation of morphological changes in platelets during storage of platelet concentrates

Article was published in

Transfusion and Haematology Today

2026 Issue 3

Popular this week